Table 2.
Univariable Analyses of Covariables Associated with Intracranial Progression-Free Survival
| Factors | HR | 95% CI | P-value |
|---|---|---|---|
| Group | |||
| Targeted-radiotherapy vs Radiotherapy-targeted | 0.178 | 0.088–0.360 | < 0.001 |
| Age at BM (year) | |||
| ≤ 50 vs > 50 | 0.665 | 0.363–1.220 | 0.188 |
| KPS | |||
| ≥ 90 vs < 90 | 0.929 | 0.475–1.815 | 0.829 |
| Number of BM | |||
| 1–3 vs > 3 | 1.144 | 0.635–2.061 | 0.654 |
| Time from the first diagnosis to BM (m) | |||
| ≥ 29 vs < 29 | 0.857 | 0.466–1.576 | 0.62 |
| Molecular subtype (n) | |||
| Luminal B (HER2+) vs HER2 overexpression | 1.130 | 0.615–2.077 | 0.693 |
| Treatment of Primary breast disease (Targeted therapy) | |||
| Yes vs No | 1.117 | 0.589–2.119 | 0.734 |
| Primary surgical treatment | |||
| Yes vs No | 1.808 | 0.932–3.507 | 0.08 |
| Ki-67 | |||
| ≥ 14 vs < 14 | 1.515 | 0.631–3.639 | 0.353 |
| Treatment after BM (Chemotherapy) | |||
| Yes vs No | 0.577 | 0.226–1.471 | 0.249 |
Abbreviations: HR, hazard ratio; CI, confidence interval; iPFS, intracranial progression-free survival; BM, brain metastasis; KPS, Karnofsky performance status; HER2, human epidermal growth factor receptor 2.